The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis

The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis

Abstract Background: The use of immune checkpoint inhibitors (ICIs) as neoadjuvant therapy is a promising novel approach in resectable non-small-cell lung cancer (NSCLC). This study aimed to investigate the prognostic value of PD-L1 in patients with NSCLC receiving neoadjuvant immune checkpoint inhi...

Full description

Saved in:
Bibliographic Details
Main Authors: Dun-Chang Mo, Jian-Feng Huang, Peng Lin, Shang-Xiao Huang, Han-Lei Wang, Peng-Hui Luo, Xiu-Juan Liang
Format: Article
Language:English
Published: Nature Portfolio 2024-10-01
Series:Scientific Reports
Subjects:
PD-L1
Immune checkpoint inhibitor
Complete pathological response
Event-free survival
Overall survival
Non-small cell lung cancer
Online Access:https://doi.org/10.1038/s41598-024-78159-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-78159-y

Similar Items